Results for tag: "Prurigo Nodularis Drug"

Prurigo Nodularis (PN) is a chronic skin disorder characterized by intensely itchy nodules. It is a rare condition, and is often misdiagnosed as eczema or scabies. Treatment of PN is challenging, and there is no single drug that is effective for all patients. Dermatological drugs used to treat PN include topical corticosteroids, topical calcineurin inhibitors, systemic immunosuppressants, and phototherapy. The Prurigo Nodularis Drug market is a small but growing segment of the Dermatological Drugs market. It is driven by the increasing prevalence of PN, as well as the need for more effective treatments. Companies in the Prurigo Nodularis Drug market include AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more